CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Sees Large Decrease in Short Interest

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a large decrease in short interest in January. As of January 15th, there was short interest totalling 471,100 shares, a decrease of 64.8% from the December 31st total of 1,340,000 shares. Based on an average trading volume of 22,860,000 shares, the short-interest ratio is currently 0.0 days.

CNS Pharmaceuticals Price Performance

Shares of CNSP traded up $0.00 during trading hours on Tuesday, hitting $0.10. The stock had a trading volume of 7,813,730 shares, compared to its average volume of 37,006,539. CNS Pharmaceuticals has a 52 week low of $0.09 and a 52 week high of $23.90. The stock has a market capitalization of $5.96 million, a price-to-earnings ratio of 0.00 and a beta of 2.52. The company’s fifty day moving average is $0.11 and its two-hundred day moving average is $0.22.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners raised CNS Pharmaceuticals to a “strong-buy” rating in a research report on Friday.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.